Boston—The addition of albumin to lactulose significantly improves outcomes for patients with cirrhosis and hepatic encephalopathy (HE), researchers have found.
The combination treatment not only increased the likelihood of reversing HE but was associated with a significant reduction in death and length of stay in the hospital, according to results of the randomized trial. Although the study size was relatively small, the improvement in outcomes was accompanied by reductions in cytokines